# Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01040403** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 233 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** olodaterol (BI 1744) low
- **DRUG:** low tiotropium bromide
- **DRUG:** olodaterol (BI 1744) high
- **DRUG:** medium tiotropium bromide
- **DRUG:** high tiotropium bromide
- **DRUG:** Placebo
- **DEVICE:** Respimat

## Key facts

- **NCT ID:** NCT01040403
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2011-02
- **Final completion:** —
- **Target enrollment:** 233 (ACTUAL)
- **Last updated:** 2015-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01040403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01040403, "Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01040403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*